<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) JUNE 24, 1996
ENZON, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 0-12957 22-237286
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification)
20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY 08854
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (908) 980-4500
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5. OTHER EVENTS
Enzon, Inc. ("Enzon" or the "Company") announced that a multi-
dose, multi-center clinical trial of its hemoglobin-based oxygen carrier,
PEG-hemoglobin, has begun in cancer patients receiving radiation therapy.
Patients entering this new trial will receive once-a-week infusions of PEG-
hemoglobin followed by five days of radiation treatment. This will be
repeated weekly for three weeks. The primary purpose of this trial is to
evaluate safety related to multiple doses of PEG-hemoglobin in patients.
It also offers an opportunity to observe tumor responses in patients
receiving the combination of PEG-hemoglobin and radiation therapy. To
date, as many as three injections of PEG-hemoglobin have been administered
to patients participating in this clinical trial.
In a previous Phase I safety trial, completed at the end of 1995,
34 normal volunteers received a single dose of PEG-hemoglobin in amounts up
to the equivalent of 1.5 units of whole blood. The dose levels in the new
trial will be approximately one-half to two-thirds of the highest dose used
in the previous Phase I safety trial. The Company believes that, at this
dose level, a sufficient amount of PEG-hemoglobin will remain in the blood
stream to increase tumor oxygenation during most of each five-day treatment
cycle.
Enzon continues to dedicate its pilot manufacturing capability
exclusively to the production of PEG-hemoglobin for additional clinical
materials and commercial process development. The existing facility at the
present scale is adequate to supply all PEG-hemoglobin needed for clinical
trials.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: July 22, 1996
ENZON, INC.
(Registrant)
By: /s/KENNETH J. ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer
